EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-FMS-02(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Fibromyalgia is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Fibromyalgia is a complex chronic pain disorder characterized by central sensitization, neuroinflammation, small-fiber polyneuropathy, dysregulated pain pathway signaling, and profound systemic fatigue.
Biological Rationale & Paracrine Action:
Explores the immunomodulatory and paracrine activity of clinical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to downregulate central microglial activation, modulate systemic pro-inflammatory cytokines, and support peripheral nerve fiber recovery.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Adults meeting the ACR 2016 diagnostic criteria for Fibromyalgia with documented chronic widespread pain (>12 months) that has failed standard pharmacotherapies (e.g., SNRIs, gabapentinoids, low-dose naltrexone) and specialized physical therapy.
Mandatory Pre-Procedure Diagnostics:
Revised Fibromyalgia Impact Questionnaire (FIQR), Widespread Pain Index (WPI $\ge 7$) and Symptom Severity (SS $\ge 5$) scores, skin punch biopsy records (assessing intraepidermal nerve fiber density, if available), complete autoimmune screen (ANA, RF, Anti-CCP to rule out primary connective tissue disease), thyroid profile, and baseline sleep studies.
Strict Safety Exclusion Parameters:
Active severe psychiatric illness with psychotic features or untreated major depression, substance dependency, active systemic or occult infections, active malignancies, or severe uncompensated cardiovascular disease.
Triage Protocol & Multi-Specialty Clearance:
Comprehensive chart review by an integrated board of neurologists, rheumatologists, and pain physicians prior to confirming international medical travel.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Widespread Pain Reduction: Decrease in resting diffuse muscle tenderness, body ache intensity, and trigger point hypersensitivity.
- Fatigue & Energy Restoration: Reductions in daily debilitating physical exhaustion and post-exertional malaise.
- Sleep Architecture: Decreased nighttime awakenings, fewer sleep interruptions, and improved restorative morning sleep quality.
- Cognitive Clarity ("Fibro Fog"): Modest gains in concentration, mental stamina, and daytime focus.
- Medication De-escalation: Potential to taper high-dose symptomatic analgesics or sleep aids under medical supervision.
Documented Procedural Risks & Limits:
- Transient post-infusion low-grade pyrexia, mild headache, or lightheadedness typically resolving within 24–48 hours.
- Temporary fatigue or transient flare-up of muscular soreness immediately following therapy.
- No Guaranteed Relief: Pain syndromes are multifactorial; biological therapy does not rewrite central neurological pathways for every individual and does not prevent stress-induced flare-ups.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Campus
Delivered exclusively within multi-specialty tertiary hospitals accredited by NABH and JCI.
Interdisciplinary Pain Board
Direct medical oversight by clinical neurologists, fellowship-trained pain specialists, and neuro-physiotherapists.
cGMP Cleanroom Rigor
Cell processing strictly complies with Indian CDSCO safety standards and international Good Manufacturing Practices.
Ethical Research Governance
Supervised by an active Institutional Ethics Committee (IEC) registered with the Department of Health Research (DHR).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with lead pain physicians to review diagnostic history, previous medication trials, and set realistic expectations.
Government Medical Visa
Priority assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation documentation.
Dedicated Case Liaison
Single multilingual point of contact coordinating airport reception, procedural scheduling, and medical records.
Structured Long-Term Follow-Up
Scheduled virtual evaluations at Months 1, 3, 6, and 12, collaborating directly with the patient's primary care physician or pain clinic back home.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Sanitized Private Transfers
Private, air-conditioned vehicle pick-up and drop-off to avoid jarring transit for patients experiencing hyperalgesia and tactile allodynia.
Low-Sensory Accommodations
Private hospital suites and partner serviced apartments (within 10 minutes of the hospital) featuring noise-insulated rooms, blackout curtains, orthopedic bedding, and walk-in showers.
Patient Amenities
Anti-inflammatory, gut-friendly nutrition plans supervised by clinical dietitians, local SIM card registration, and 24/7 nursing access.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Fibromyalgia
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Review of Mesenchymal Stem Cells in Rheumatic Diseases and Fibromyalgia
Alzahrani, A., et al. (2025). Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases. Immunity, Inflammation and Disease, 13(5), e70092. Clinical Significance: Summarizes translational and early clinical findings of mesenchymal stem cell applications across rheumatic disorders and refractory widespread pain syndromes (including fibromyalgia). Evaluates how MSC paracrine secretion and immunomodulatory signaling dampen pathogenic T-cell responses, decrease circulating inflammatory cytokines, and modulate systemic pain signaling pathways.
Modulation of Neuroinflammation and Glial Reactivity by Mesenchymal Stem Cells
Mammadov, E., et al. (2026). Mesenchymal Stem Cell Therapy Modulates Peripheral-Central Immune Interactions and Attenuates Neuroinflammation-Driven Cognitive Dysfunction. International Journal of Molecular Sciences, 27(3), 1182. Clinical Significance: Directly investigates the mechanisms of systemic umbilical cord-derived MSC (hUC-MSC) administration in downregulating central microglial activation, reducing pro-inflammatory cytokines, and restoring anti-inflammatory IL-10 levels. Provides experimental evidence supporting the hypothesis that targeting peripheral-central immune interactions can alleviate neuroinflammation-driven central sensitization and cognitive impairment ("fibro fog").
Systematic Review of Stem Cell Therapy for Modulating Neuroinflammation and Neuropathic Pain
Suda, O., et al. (2021). Stem Cell Therapy for Modulating Neuroinflammation in Neuropathic Pain. International Journal of Molecular Sciences, 22(9), 4853. Clinical Significance: Synthesizes preclinical and emerging clinical trial data evaluating bone marrow, adipose, and umbilical cord MSCs in refractory neuropathic and nociplastic pain conditions. Outlines how stem cell-mediated suppression of spinal cord astroglial and microglial reactivity interrupts continuous pain processing and secondary allodynia.
Clinical Trial on Autologous Adipose-Derived Cellular Therapy for Neuropathic Pain
Centeno, C., et al. (2021). Safety and Efficacy of Percutaneous Cellular Therapies in Chronic Intractable Neuropathy and Central Pain Syndromes. Pain Physician, 24(2), E215–E228. Clinical Significance: Assesses the clinical safety profile and patient-reported outcomes following systemic and perineural infusions of autologous regenerative cell fractions in patients with chronic intractable neuropathic pain and overlapping centralized sensitization. Demonstrates durable reductions in Numeric Rating Scale (NRS) pain scores and functional improvements without major cell-related adverse reactions.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell therapy for Fibromyalgia is classified as strictly investigational and experimental. It is not recognized by the Central Drugs Standard Control Organisation (CDSCO) as an approved standard commercial treatment or cure. It is administered strictly within ethics-committee-approved clinical research protocols. Patients are strongly advised never to abruptly stop prescribed neurological, analgesic, or psychological therapies without direct specialist supervision.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.